

**The notice contains important information that requires your immediate attention.
Should you have any query about this notice, please seek independent professional advice.**

March 21, 2024

**To Policyowners of Manulife Investment Plus 2
(the “Plan”)**

Various Changes of the Underlying Funds

We would like to notify you of the following changes with regard to the following underlying funds (each an “**Underlying Fund**” and collectively, the “**Underlying Funds**”) corresponding to the following investment choices under the Plan, following our receipt of the respective notices of the Underlying Funds.

Name of Investment Choice	Name of Underlying Fund	Share Class of Underlying Fund
Franklin Biotechnology Discovery Fund	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund	Class A Acc (USD)
Franklin Income Fund (dist)	Franklin Templeton Investment Funds – Franklin Income Fund	Class A (Mdis) USD
Franklin U.S. Opportunities Fund	Franklin Templeton Investment Funds – Franklin U.S. Opportunities Fund	Class A Acc USD
Templeton Frontier Markets Fund	Franklin Templeton Investment Funds – Templeton Frontier Markets Fund	Class A (acc)
Templeton Global Bond Fund	Franklin Templeton Investment Funds – Templeton Global Bond Fund	Class A (acc) USD
Templeton Global Total Return Fund (dist)	Franklin Templeton Investment Funds – Templeton Global Total Return Fund	Class A (Mdis) USD
UBS Emerging Markets Sustainable Leaders	UBS (Lux) Equity Fund - Emerging Markets Sustainable Leaders (USD)	Class P-acc

each a “**Templeton Underlying Fund**” and collectively, the “**Templeton Underlying Funds**”

the “**UBS Underlying Fund**”

1. Changes to the Templeton Underlying Funds

According to the notice from Franklin Templeton Investment Funds (the Templeton Underlying Funds being sub-funds of which) dated February 28, 2024, the explanatory memorandum of Franklin Templeton Investment Funds (the “**Explanatory Memorandum**”) shall be updated to reflect the below. Unless otherwise stated, the changes set out below took effect as of December 31, 2023.

- a) In relation to the pre-contractual disclosures of the Franklin Templeton Investment Funds - Templeton Global Bond Fund, the disclosure relating to good governance shall be updated to clarify that while good governance requirement is technically not applicable to sovereign, the investment team will try to engage with governments on that subject when possible. As a result, the fifth paragraph under the question headed “What is the policy to assess good governance practices of the investee companies?” in the pre-contractual disclosures of the Franklin Templeton Investment Funds - Templeton Global Bond Fund shall be amended as follows (with revisions in markups):

“Sovereign governance is regularly assessed and monitored as part of the process. ~~The~~ From time to time, the Investment Manager ~~maintains contacts~~ has discussions with governments, central banks and other institutions at various levels. ~~On a frequent basis, Certain of these discussions are held particularly around~~ may include governance and economic best practices, and ~~in those meetings the Investment Manager shares~~ may share its views while also trying to better understand government stances on economic policies and governance, as well as sustainability and social topics to facilitate the investment decision making.”

- b) The first paragraph under the sub-section headed “SUSPENSION AND TERMINATION” in the section headed “ADDITIONAL INFORMATION” shall be amended as follows (with revisions in mark-up):

“The Company may, after consultation with the Depositary, having regard to the best interests of Shareholders, suspend the determination of the Net Asset Value of Shares of any Fund and hence the issue, redemption or switching of Shares in the Funds when: (a) there is a closure or suspension of trading on any market on which a substantial portion of that Fund’s investments are normally quoted, listed, or dealt in; (b) the existence of any state of affairs which constitutes an emergency as a result of which the disposal or valuation of investments attributable to that Fund is impracticable; (c) when there is a breakdown or restriction in the means of communication normally employed in determining the price or value of any of that Fund’s investments or the current price or values on any stock exchange or market; (d) the value of that Fund’s investments cannot, in the opinion of the Board of Directors, be transferred or repatriated at normal rates of exchange; (e) any period when the Net Asset Value of Shares of any Fund may not be determined

accurately; (f) during any period when in the opinion of the Board of Directors there exists unusual circumstances where it would be impractical or unfair towards the investors to continue dealing in the Shares of any Fund or circumstances where a failure to do so might result in the investors or a Fund incurring any liability to taxation or suffering other pecuniary disadvantage or other detriment which the investors or a Fund might not otherwise have suffered; (g) if the Company or a Fund is being or may be wound-up, on or following the date on which such decision is taken by the Board of Directors or notice is given to Shareholders of a general meeting at which a resolution to wind-up the Company or a Fund is to be proposed; (h) in the case of a merger, if the Board of Directors deems this to be justified for the protection of the Shareholders; or (i) in the case of a suspension of the calculation of the net asset value of one or several underlying investment funds in which a Fund has invested a substantial portion of assets. In accordance with the Law of 17 December 2010, the issue and redemption of Shares shall be prohibited: (a) during the period where the Company has no depositary; and (b) where the Depositary is put into liquidation or declared bankrupt or seeks an arrangement with the creditors, a suspension of payment or a controlled management or is the subject of similar proceedings."

- c) Updates to the information relating to the board of directors of Franklin Templeton Investment Funds, as well as the board of managers and conducting officers of the management company of the Templeton Underlying Funds.
- d) Other taxation, administrative, clarificatory and/or editorial updates.

The changes set out above do not amount to a material change to the Templeton Underlying Funds. There is no material change or increase in the overall risk profiles of any of the Templeton Underlying Funds following the above changes. Further, the above changes do not have a material adverse impact on rights or interests of the investors of the Templeton Underlying Funds (including changes that may limit the ability of investors of the Templeton Underlying Funds in exercising their rights), and the above changes are not expected to give rise to any change in the fee level or fee structure of any of the Templeton Underlying Funds.

Any costs and/or expenses incurred in connection with the above changes shall be borne by the management company of the Templeton Underlying Funds, other than the cost of publishing notice from Franklin Templeton Investment Funds, which is estimated to be approximately HKD120,000 and which shall be charged and allocated to the sub-funds of Franklin Templeton Investment Funds based on the pro rata share of the net asset value of the sub-funds of Franklin Templeton Investment Funds.

2. Changes to the UBS Underlying Fund

According to the notice from UBS (Lux) Equity Fund (the UBS Underlying Fund being a sub-fund of which) dated February 22, 2024 and March 20, 2024, the board of directors of the management company of UBS (Lux) Equity Fund (the "**Board of Directors**") informs the following updates and administrative changes that will be reflected in the Hong Kong offering documents of the UBS Underlying Fund on or around April 22, 2024:

- changes to the Board of Directors and conducting officers of the management company of UBS (Lux) Equity Fund;
- updates to the general descriptions of the depositary of the UBS Underlying Fund;
- elaboration on disclosures relating to when a reduced tax d'abonnement is payable to the Grand Duchy of Luxembourg;
- updates to reflect that 30% of gross revenues received from securities lending will be retained as fees by UBS Switzerland AG as the securities lending service provider of the UBS Underlying Fund, who is responsible for the ongoing securities lending activities and collateral management, and 10% will be retained as cost/fees by UBS Europe SE, Luxembourg Branch as the securities lending agent of the UBS Underlying Fund, who is responsible for transactions management, ongoing operational activities and collateral safekeeping;
- amendments to reflect the change in the name of the UBS ESG Consensus Score to UBS Blended ESG Score used internally by the portfolio managers of the UBS Underlying Fund
- elaboration to the SFDR¹ Annex of the UBS Underlying Fund to, amongst others, disclose the principal adverse impacts indicators that the portfolio managers of the UBS Underlying Fund will use to assess "do no significant harm" within the environmental, environmental, social or governance ("**ESG**") risk dashboard;
- updates to the SFDR Annexes of the UBS Underlying Fund to state, amongst others, that the UBS Underlying Fund will not invest in fossil gas and/or nuclear energy related activities that comply with the European Union ("**EU**") Taxonomy, wherein to comply with the EU Taxonomy i) the criteria for "fossil fuel" include limitations on emissions and switching to renewable power or low carbon fuels by the end of 2035; and ii) the criteria for "nuclear energy" include comprehensive safety and waste management rules; and
- other updates and clarificatory changes.

Please refer to the respective notices and latest offering documents of the Underlying Funds for further information relating to the above changes.

¹ SFDR refers to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector.

If you have any enquiry, please do not hesitate to contact your Manulife Insurance Advisor or call our Customer Service Hotline at (852) 2108 1110 during office hours: 9:00am - 6:00pm, Monday to Friday.

Customer Services

Individual Financial Products

Manulife (International) Limited

Incorporated in Bermuda with limited liability